EMA’s new policy on access to clinical data: About to privatise pharmaceutical knowledge? The proof will be in the pudding
Attachment: 20140624_emanewpolicyaccessclinicaldata.pdf
Attachment: 20140624_emanewpolicyaccessclinicaldata.pdf
Category: Publications
Attachment: 20140624_emanewpolicyaccessclinicaldata.pdf
Backpedalling on EMA’s “proactive publication of clinical-data” draft policy: Was it all just a window-dressing exercise? Who or what is the EMA afraid of?
Attachment: 20140520_ematransparencypolicy.pdf
Newsletter March 2014
The November 2014 issue of the ISDB Newsletter (vol 29, issue 2) includes:
- preliminary announcement of the ISDB General Assembly, scheduled to take place in Pamplona, Spain in June 2015
- draft program for the 2015 ISDB General Assembly
EU Regulation on clinical trials: An urgent call for support to clinical data transparency
Attachment: letter_to_corepers_ctr.pdf
TRANSPARENCY IN THE PUBLIC INTEREST: How the EMA policy on publication and access to clinical-trial data could help save lives
The European Medicines Agency (EMA) draft policy on “publication and access to clinical-trial data” could pave the way to a new era in the disclosure of clinical data on medicines.
Attachment: sept2013_ema_transparencypolicy.pdf